Unibest

Pharmaceutical intermediates

Canagliflozin Intermediates

4 pharmaceutical intermediates for Canagliflozin. Indication: Type 2 Diabetes Mellitus; Diabetic Nephropathy.

Submit a ProjectAll intermediates

About Canagliflozin

Originator
Mitsubishi Tanabe Pharma Corporation
Indication
Type 2 Diabetes Mellitus; Diabetic Nephropathy
Approved Date
03/29/2013
DS/DP
07/14/2027

Available intermediates

4 intermediates currently listed for Canagliflozin. Request specifications, documentation or a quotation for any item below.

Canagliflozin intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
2-(4-Fluorophenyl)-5-[(5-iodo-2-methylphenyl)methyl]thiophene898566-17-1//
2-(4-Fluorophenyl)-5-[(5-bromo-2-methylphenyl)methyllthiophene1030825-20-7//
2-(4-Fluorophenyl)thiophene58861-48-6//
(1S)-1,5-Anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4methylphenyl]-D-glucitol tetraacetate866607-35-4//

Other programs under C

Cabozantinib S-malateCalcipotriolCalcitriolCamlipixantCangrelor TetrasodiumCapivasertib Capmatinib HydrochlorideCarfilzomib

Building toward Canagliflozin?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →